HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -172.27 Billion KRW | -86.9% |
| 2022 | -59.42 Billion KRW | 33.56% |
| 2021 | -87.8 Billion KRW | -8.57% |
| 2020 | -80.82 Billion KRW | -76.02% |
| 2019 | -40 Billion KRW | -63.93% |
| 2018 | 27.59 Billion KRW | -17.7% |
| 2017 | -27.33 Billion KRW | -9.46% |
| 2016 | -20.72 Billion KRW | -171.93% |
| 2015 | 14.82 Billion KRW | -425.19% |
| 2014 | 2.46 Billion KRW | 193.41% |
| 2013 | -5.93 Billion KRW | -186.74% |
| 2012 | -1.94 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -35.91 Billion KRW | -4026.16% |
| 2024 Q1 | -34.27 Billion KRW | 98.48% |
| 2023 Q4 | -22.78 Billion KRW | 15.72% |
| 2023 Q2 | -31.12 Billion KRW | -22.67% |
| 2023 Q1 | -25.37 Billion KRW | -83.91% |
| 2023 Q3 | -27.03 Billion KRW | 13.16% |
| 2023 FY | - KRW | -86.9% |
| 2022 Q3 | -32.61 Billion KRW | -242.23% |
| 2022 Q4 | -13.79 Billion KRW | 57.69% |
| 2022 Q2 | -9.52 Billion KRW | -297.2% |
| 2022 Q1 | -2.39 Billion KRW | 92.64% |
| 2022 FY | - KRW | 33.56% |
| 2021 Q2 | -16.2 Billion KRW | 9.09% |
| 2021 Q4 | -32.58 Billion KRW | -53.72% |
| 2021 Q3 | -21.19 Billion KRW | -30.83% |
| 2021 FY | - KRW | -8.57% |
| 2021 Q1 | -17.82 Billion KRW | -4.28% |
| 2020 Q4 | -17.08 Billion KRW | 11.23% |
| 2020 FY | - KRW | -76.02% |
| 2020 Q2 | -38.91 Billion KRW | -599.12% |
| 2020 Q1 | -5.56 Billion KRW | 56.26% |
| 2020 Q3 | -19.25 Billion KRW | 50.53% |
| 2019 Q2 | -11.09 Billion KRW | -16.79% |
| 2019 FY | - KRW | -63.93% |
| 2019 Q4 | -12.72 Billion KRW | 0.47% |
| 2019 Q3 | -12.78 Billion KRW | -15.26% |
| 2019 Q1 | -9.49 Billion KRW | 27.38% |
| 2018 Q4 | -13.07 Billion KRW | -134.55% |
| 2018 FY | - KRW | -17.7% |
| 2018 Q2 | -4.37 Billion KRW | 11.73% |
| 2018 Q1 | -4.95 Billion KRW | 57.96% |
| 2018 Q3 | -5.57 Billion KRW | -27.56% |
| 2017 Q1 | -3.28 Billion KRW | 73.98% |
| 2017 FY | - KRW | -9.46% |
| 2017 Q4 | -11.77 Billion KRW | -172.53% |
| 2017 Q3 | -4.32 Billion KRW | 1.33% |
| 2017 Q2 | -4.37 Billion KRW | -33.42% |
| 2016 FY | - KRW | -171.93% |
| 2016 Q4 | -12.61 Billion KRW | -133.19% |
| 2016 Q3 | -5.4 Billion KRW | -99.32% |
| 2016 Q2 | -2.71 Billion KRW | -180.6% |
| 2016 Q1 | -967.26 Million KRW | 80.78% |
| 2015 Q1 | -526.74 Million KRW | -171.71% |
| 2015 Q4 | -5.03 Billion KRW | -499.75% |
| 2015 Q3 | -839.01 Million KRW | 44.23% |
| 2015 Q2 | -1.5 Billion KRW | -185.59% |
| 2015 FY | - KRW | -425.19% |
| 2014 Q2 | -300.62 Million KRW | -130.65% |
| 2014 Q4 | 734.59 Million KRW | -29.73% |
| 2014 Q1 | 980.75 Million KRW | 138.97% |
| 2014 FY | - KRW | 193.41% |
| 2014 Q3 | 1.04 Billion KRW | 447.74% |
| 2013 Q1 | -702.3 Million KRW | 54.07% |
| 2013 Q3 | 1.28 Billion KRW | 283.49% |
| 2013 FY | - KRW | -186.74% |
| 2013 Q4 | -2.51 Billion KRW | -295.58% |
| 2013 Q2 | -701.33 Million KRW | 0.14% |
| 2012 Q4 | -1.52 Billion KRW | -1172.82% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | -120.14 Million KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -2663.244% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 1684.604% |
| Bioneer Corporation | 10.04 Billion KRW | 1815.376% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -39248.822% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | -788.417% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | -302.547% |
| Helixmith Co., Ltd | -53 Billion KRW | -225.029% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 345.803% |
| Medy-Tox Inc. | 32.69 Billion KRW | 626.876% |
| Peptron, Inc. | -12.65 Billion KRW | -1261.832% |
| Amicogen, Inc. | 13.95 Billion KRW | 1334.694% |
| Genexine, Inc. | -40.87 Billion KRW | -321.445% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 2193.408% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | -141.338% |
| ALTEOGEN Inc. | 440.04 Million KRW | 39250.549% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 265.249% |
| SillaJen, Inc. | -17.35 Billion KRW | -892.82% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 1665.067% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -1447.174% |
| Genomictree Inc. | -6.33 Billion KRW | -2620.835% |
| MedPacto, Inc. | -32.6 Billion KRW | -428.323% |
| D&D Pharmatech | -9.05 Billion KRW | -1801.972% |
| EASY BIO,Inc. | 24.32 Billion KRW | 808.289% |
| GI Innovation, Inc. | -51.33 Billion KRW | -235.626% |